Pfizer-Best Biotech Stock to Buy in July

  Pfizer-Best Biotech Stock to Buy in July In These Days Of Positivity, It's Time To Enter Pfizer. In the past five years, biotech stocks have performed below the S&P 500 benchmark. Pharmaceutical pricing reduces the profitability of companies in the sector due to increasing innovation costs and increasing generic competition in medicine. Let's take a look at why Pfizer is a great option for investors.

Pfizer PFE (NYSE) $39,61 +0,36 (+%0,92)

Pfizer has always fought on the front line in the fight against the coronavirus pandemic with its coronavirus vaccine, Comirnaty. The company has revenue estimates of over $26 billion for the full year, with vaccine sales in the first quarter of 2021 alone reaching a value of $3,462 billion. Despite everything, it is necessary to know that the coronavirus vaccine is not a one-time support that will increase the profitability of the company. According to a recent study in Israel, the increase in the deadly and more contagious delta variant Comirnaty's effectiveness has decreased from 95% to 64% overall. Similarly, in clinical studies, vaccine protection against serious or critical illness has decreased from 100% to 93%. Pfizer's expectation is that total vaccine and biopharma sales will reach $71,5 billion this year. This represents 70,6% year-on-year growth from 2020 revenue when taking into account the division of the generics business Upjohn. At the same time, Pfizer forecasts earnings per share (EPS) to rise 62% from 2020 to $3.60. The increase in the demand for vaccines shows that the increase will continue to grow in the next 2 years. Despite all these data, it is important to remember that the stock is still cheap, earnings (P/E) show 11 and Pfizer stock shows a serious dividend yield of 4% per year.  

Source: The Motley Fool

 

You may also be interested in:

 

Amazon Concerns-Reliance’s JioMart Acquisition In India